Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

We previously reported durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) patients treated with CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell immunotherapy after ibrutinib failure. Because preclinical studies showed that ibrutinib could improv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2020-05, Vol.135 (19), p.1650-1660
Hauptverfasser:	Gauthier, Jordan, Hirayama, Alexandre V., Purushe, Janaki, Hay, Kevin A., Lymp, James, Li, Daniel H., Yeung, Cecilia C.S., Sheih, Alyssa, Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Phi, Tinh-Doan, Steinmetz, Rachel N., Shadman, Mazyar, Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - analogs & derivatives Adenine - therapeutic use Adult Aged Antigens, CD19 - immunology Clinical Trials and Observations Combined Modality Therapy Drug Resistance, Neoplasm Feasibility Studies Female Follow-Up Studies Humans Immunotherapy, Adoptive - methods Leukemia, Lymphocytic, Chronic, B-Cell - immunology Leukemia, Lymphocytic, Chronic, B-Cell - pathology Leukemia, Lymphocytic, Chronic, B-Cell - therapy Male Middle Aged Piperidines - therapeutic use Prognosis Receptors, Antigen, T-Cell - immunology Retrospective Studies Salvage Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!